Grace Therapeutics, Inc.
GTx-104
aneurysmal subarachnoid hemorrhage
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews GTx-104 for aneurysmal subarachnoid hemorrhage around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“A Type A meeting with the FDA has been scheduled to potentially clarify the path forward and determine the appropriate next steps.”